▶ 調査レポート

世界の前立腺がん診断/治療市場(~2028年):アンドロゲン受容体指向療法、タキサンベース化学療法

• 英文タイトル:Global Prostate Cancer Diagnostics and Therapy Market Insights, Forecast to 2028

Global Prostate Cancer Diagnostics and Therapy Market Insights, Forecast to 2028「世界の前立腺がん診断/治療市場(~2028年):アンドロゲン受容体指向療法、タキサンベース化学療法」(市場規模、市場予測)調査レポートです。• レポートコード:MRC2Q12-16834
• 出版社/出版日:QYResearch / 2022年12月
• レポート形態:英文、PDF、108ページ
• 納品方法:Eメール(納期:3営業日)
• 産業分類:医療
• 販売価格(消費税別)
  Single User¥725,200 (USD4,900)▷ お問い合わせ
  Enterprise License¥1,450,400 (USD9,800)▷ お問い合わせ
• ご注文方法:お問い合わせフォーム記入又はEメールでご連絡ください。
• お支払方法:銀行振込(納品後、ご請求書送付)
レポート概要
新型コロナウイルス感染症とロシア・ウクライナ戦争の影響により、前立腺がん診断/治療のグローバル市場は 2022にxxxドルと推定され、2028年までにxxxドルの規模に達し、2022年から2028年の予測期間中にxxx%のCAGRで成長すると予測されています。
前立腺がん診断/治療のアメリカ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
前立腺がん診断/治療の中国市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。
前立腺がん診断/治療のヨーロッパ市場は、2023年から2028年の予測期間中にxxx%のCAGRで、2022年xxxドルから2028年xxxドルに達すると推定されています。

生産面において、本レポートは2017年から2022年までの前立腺がん診断/治療の生産、成長率、メーカー別市場シェア、地域別市場シェア、および2028年までの予測を調査しています。販売面において、本レポートは2017年から2022年までの地域別、企業別、タイプ別、アプリケーション別の前立腺がん診断/治療の売上および2028年までの予測に焦点を当てています。

前立腺がん診断/治療のグローバル主要企業には、Ipsen SA、Pfizer Inc.、Johnson & Johnson Services Inc.、Bayer AG、Abbvie Inc.、Merck & Co. Inc.、AstraZeneca PLC、Thermo Fisher Scientific、Dendreon Pharmaceuticals LLC、F. Hoffmann-La Roche Ltd、Hologic Inc.、Astellas Pharma Inc.、Koninklijke Philips NV、Sanofi-Aventisなどがあります。2021年、世界のトップ5プレイヤーは売上ベースで約xxx%の市場シェアを占めています。

前立腺がん診断/治療市場は、タイプとアプリケーションによって区分されます。世界の前立腺がん診断/治療市場のプレーヤー、利害関係者、およびその他の参加者は、当レポートを有益なリソースとして使用することで優位に立つことができます。セグメント分析は、2017年~2028年期間のタイプ別およびアプリケーション別の販売量、売上、予測に焦点を当てています。

【タイプ別セグメント】
アンドロゲン受容体指向療法、タキサンベース化学療法

【アプリケーション別セグメント】
病院、クリニック、その他

【掲載地域】
北米:アメリカ、カナダ
ヨーロッパ:ドイツ、フランス、イギリス、イタリア、ロシア
アジア太平洋:日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア
中南米:メキシコ、ブラジル、アルゼンチン
中東・アフリカ:トルコ、サウジアラビア、UAE

【目次(一部)】

・調査の範囲
- 前立腺がん診断/治療製品概要
- タイプ別市場(アンドロゲン受容体指向療法、タキサンベース化学療法)
- アプリケーション別市場(病院、クリニック、その他)
- 調査の目的
・エグゼクティブサマリー
- 世界の前立腺がん診断/治療販売量予測2017-2028
- 世界の前立腺がん診断/治療売上予測2017-2028
- 前立腺がん診断/治療の地域別販売量
- 前立腺がん診断/治療の地域別売上
- 北米市場
- ヨーロッパ市場
- アジア太平洋市場
- 中南米市場
- 中東・アフリカ市場
・メーカーの競争状況
- 主要メーカー別前立腺がん診断/治療販売量
- 主要メーカー別前立腺がん診断/治療売上
- 主要メーカー別前立腺がん診断/治療価格
- 競争状況の分析
- 企業M&A動向
・タイプ別市場規模(アンドロゲン受容体指向療法、タキサンベース化学療法)
- 前立腺がん診断/治療のタイプ別販売量
- 前立腺がん診断/治療のタイプ別売上
- 前立腺がん診断/治療のタイプ別価格
・アプリケーション別市場規模(病院、クリニック、その他)
- 前立腺がん診断/治療のアプリケーション別販売量
- 前立腺がん診断/治療のアプリケーション別売上
- 前立腺がん診断/治療のアプリケーション別価格
・北米市場
- 北米の前立腺がん診断/治療市場規模(タイプ別、アプリケーション別)
- 主要国別の前立腺がん診断/治療市場規模(アメリカ、カナダ)
・ヨーロッパ市場
- ヨーロッパの前立腺がん診断/治療市場規模(タイプ別、アプリケーション別)
- 主要国別の前立腺がん診断/治療市場規模(ドイツ、フランス、イギリス、イタリア、ロシア)
・アジア太平洋市場
- アジア太平洋の前立腺がん診断/治療市場規模(タイプ別、アプリケーション別)
- 主要国別の前立腺がん診断/治療市場規模(日本、中国、韓国、インド、オーストラリア、台湾、インドネシア、タイ、マレーシア)
・中南米市場
- 中南米の前立腺がん診断/治療市場規模(タイプ別、アプリケーション別)
- 主要国別の前立腺がん診断/治療市場規模(メキシコ、ブラジル、アルゼンチン)
・中東・アフリカ市場
- 中東・アフリカの前立腺がん診断/治療市場規模(タイプ別、アプリケーション別)
- 主要国別の前立腺がん診断/治療市場規模(トルコ、サウジアラビア)
・企業情報
Ipsen SA、Pfizer Inc.、Johnson & Johnson Services Inc.、Bayer AG、Abbvie Inc.、Merck & Co. Inc.、AstraZeneca PLC、Thermo Fisher Scientific、Dendreon Pharmaceuticals LLC、F. Hoffmann-La Roche Ltd、Hologic Inc.、Astellas Pharma Inc.、Koninklijke Philips NV、Sanofi-Aventis
・産業チェーン及び販売チャネル分析
- 前立腺がん診断/治療の産業チェーン分析
- 前立腺がん診断/治療の原材料
- 前立腺がん診断/治療の生産プロセス
- 前立腺がん診断/治療の販売及びマーケティング
- 前立腺がん診断/治療の主要顧客
・マーケットドライバー、機会、課題、リスク要因分析
- 前立腺がん診断/治療の産業動向
- 前立腺がん診断/治療のマーケットドライバー
- 前立腺がん診断/治療の課題
- 前立腺がん診断/治療の阻害要因
・主な調査結果

Market Analysis and Insights: Global Prostate Cancer Diagnostics and Therapy Market
The global Prostate Cancer Diagnostics and Therapy market size is projected to reach US$ million by 2028, from US$ million in 2021, at a CAGR of % during 2022-2028.
Fully considering the economic change by this health crisis, Androgen Receptor-Directed Therapy accounting for % of the Prostate Cancer Diagnostics and Therapy global market in 2021, is projected to value US$ million by 2028, growing at a revised % CAGR from 2022 to 2028. While Hospitals segment is altered to an % CAGR throughout this forecast period.
China Prostate Cancer Diagnostics and Therapy market size is valued at US$ million in 2021, while the North America and Europe Prostate Cancer Diagnostics and Therapy are US$ million and US$ million, severally. The proportion of the North America is % in 2021, while China and Europe are % and % respectively, and it is predicted that China proportion will reach % in 2028, trailing a CAGR of % through the analysis period 2022-2028. Japan, South Korea, and Southeast Asia are noteworthy markets in Asia, with CAGR %, %, and % respectively for the next 6-year period. As for the Europe Prostate Cancer Diagnostics and Therapy landscape, Germany is projected to reach US$ million by 2028 trailing a CAGR of % over the forecast period 2022-2028.
With industry-standard accuracy in analysis and high data integrity, the report makes a brilliant attempt to unveil key opportunities available in the global Prostate Cancer Diagnostics and Therapy market to help players in achieving a strong market position. Buyers of the report can access verified and reliable market forecasts, including those for the overall size of the global Prostate Cancer Diagnostics and Therapy market in terms of revenue.
Overall, the report proves to be an effective tool that players can use to gain a competitive edge over their competitors and ensure lasting success in the global Prostate Cancer Diagnostics and Therapy market. All of the findings, data, and information provided in the report are validated and revalidated with the help of trustworthy sources. The analysts who have authored the report took a unique and industry-best research and analysis approach for an in-depth study of the global Prostate Cancer Diagnostics and Therapy market.
Global Prostate Cancer Diagnostics and Therapy Scope and Market Size
Prostate Cancer Diagnostics and Therapy market is segmented by players, region (country), by Treatment Method and by Application. Players, stakeholders, and other participants in the global Prostate Cancer Diagnostics and Therapy market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Treatment Method and by Application for the period 2017-2028.
Segment by Treatment Method
Androgen Receptor-Directed Therapy
Taxane-Based Chemotherapy
Segment by Application
Hospitals
Clinics
Others
By Company
Ipsen SA
Pfizer Inc.
Johnson & Johnson Services Inc.
Bayer AG
Abbvie Inc.
Merck & Co. Inc.
AstraZeneca PLC
Thermo Fisher Scientific
Dendreon Pharmaceuticals LLC
F. Hoffmann-La Roche Ltd
Hologic Inc.
Astellas Pharma Inc.
Koninklijke Philips NV
Sanofi-Aventis
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA

レポート目次

1 Report Business Overview
1.1 Study Scope
1.2 Market Analysis by Treatment Method
1.2.1 Global Prostate Cancer Diagnostics and Therapy Market Size Growth Rate by Treatment Method, 2017 VS 2021 VS 2028
1.2.2 Androgen Receptor-Directed Therapy
1.2.3 Taxane-Based Chemotherapy
1.3 Market by Application
1.3.1 Global Prostate Cancer Diagnostics and Therapy Market Size Growth Rate by Application, 2017 VS 2021 VS 2028
1.3.2 Hospitals
1.3.3 Clinics
1.3.4 Others
1.4 Study Objectives
1.5 Years Considered
2 Global Growth Trends
2.1 Global Prostate Cancer Diagnostics and Therapy Market Perspective (2017-2028)
2.2 Prostate Cancer Diagnostics and Therapy Growth Trends by Region
2.2.1 Prostate Cancer Diagnostics and Therapy Market Size by Region: 2017 VS 2021 VS 2028
2.2.2 Prostate Cancer Diagnostics and Therapy Historic Market Size by Region (2017-2022)
2.2.3 Prostate Cancer Diagnostics and Therapy Forecasted Market Size by Region (2023-2028)
2.3 Prostate Cancer Diagnostics and Therapy Market Dynamics
2.3.1 Prostate Cancer Diagnostics and Therapy Industry Trends
2.3.2 Prostate Cancer Diagnostics and Therapy Market Drivers
2.3.3 Prostate Cancer Diagnostics and Therapy Market Challenges
2.3.4 Prostate Cancer Diagnostics and Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Prostate Cancer Diagnostics and Therapy Players by Revenue
3.1.1 Global Top Prostate Cancer Diagnostics and Therapy Players by Revenue (2017-2022)
3.1.2 Global Prostate Cancer Diagnostics and Therapy Revenue Market Share by Players (2017-2022)
3.2 Global Prostate Cancer Diagnostics and Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Prostate Cancer Diagnostics and Therapy Revenue
3.4 Global Prostate Cancer Diagnostics and Therapy Market Concentration Ratio
3.4.1 Global Prostate Cancer Diagnostics and Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Prostate Cancer Diagnostics and Therapy Revenue in 2021
3.5 Prostate Cancer Diagnostics and Therapy Key Players Head office and Area Served
3.6 Key Players Prostate Cancer Diagnostics and Therapy Product Solution and Service
3.7 Date of Enter into Prostate Cancer Diagnostics and Therapy Market
3.8 Mergers & Acquisitions, Expansion Plans
4 Prostate Cancer Diagnostics and Therapy Breakdown Data by Treatment Method
4.1 Global Prostate Cancer Diagnostics and Therapy Historic Market Size by Treatment Method (2017-2022)
4.2 Global Prostate Cancer Diagnostics and Therapy Forecasted Market Size by Treatment Method (2023-2028)
5 Prostate Cancer Diagnostics and Therapy Breakdown Data by Application
5.1 Global Prostate Cancer Diagnostics and Therapy Historic Market Size by Application (2017-2022)
5.2 Global Prostate Cancer Diagnostics and Therapy Forecasted Market Size by Application (2023-2028)
6 North America
6.1 North America Prostate Cancer Diagnostics and Therapy Market Size (2017-2028)
6.2 North America Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method
6.2.1 North America Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2017-2022)
6.2.2 North America Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2023-2028)
6.2.3 North America Prostate Cancer Diagnostics and Therapy Market Share by Treatment Method (2017-2028)
6.3 North America Prostate Cancer Diagnostics and Therapy Market Size by Application
6.3.1 North America Prostate Cancer Diagnostics and Therapy Market Size by Application (2017-2022)
6.3.2 North America Prostate Cancer Diagnostics and Therapy Market Size by Application (2023-2028)
6.3.3 North America Prostate Cancer Diagnostics and Therapy Market Share by Application (2017-2028)
6.4 North America Prostate Cancer Diagnostics and Therapy Market Size by Country
6.4.1 North America Prostate Cancer Diagnostics and Therapy Market Size by Country (2017-2022)
6.4.2 North America Prostate Cancer Diagnostics and Therapy Market Size by Country (2023-2028)
6.4.3 United States
6.4.4 Canada
7 Europe
7.1 Europe Prostate Cancer Diagnostics and Therapy Market Size (2017-2028)
7.2 Europe Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method
7.2.1 Europe Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2017-2022)
7.2.2 Europe Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2023-2028)
7.2.3 Europe Prostate Cancer Diagnostics and Therapy Market Share by Treatment Method (2017-2028)
7.3 Europe Prostate Cancer Diagnostics and Therapy Market Size by Application
7.3.1 Europe Prostate Cancer Diagnostics and Therapy Market Size by Application (2017-2022)
7.3.2 Europe Prostate Cancer Diagnostics and Therapy Market Size by Application (2023-2028)
7.3.3 Europe Prostate Cancer Diagnostics and Therapy Market Share by Application (2017-2028)
7.4 Europe Prostate Cancer Diagnostics and Therapy Market Size by Country
7.4.1 Europe Prostate Cancer Diagnostics and Therapy Market Size by Country (2017-2022)
7.4.2 Europe Prostate Cancer Diagnostics and Therapy Market Size by Country (2023-2028)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size (2017-2028)
8.2 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method
8.2.1 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2017-2022)
8.2.2 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2023-2028)
8.2.3 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Share by Treatment Method (2017-2028)
8.3 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Application
8.3.1 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Application (2017-2022)
8.3.2 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Application (2023-2028)
8.3.3 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Share by Application (2017-2028)
8.4 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Region
8.4.1 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Region (2017-2022)
8.4.2 Asia-Pacific Prostate Cancer Diagnostics and Therapy Market Size by Region (2023-2028)
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 Southeast Asia
8.4.7 India
8.4.8 Australia
9 Latin America
9.1 Latin America Prostate Cancer Diagnostics and Therapy Market Size (2017-2028)
9.2 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method
9.2.1 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2017-2022)
9.2.2 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2023-2028)
9.2.3 Latin America Prostate Cancer Diagnostics and Therapy Market Share by Treatment Method (2017-2028)
9.3 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Application
9.3.1 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Application (2017-2022)
9.3.2 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Application (2023-2028)
9.3.3 Latin America Prostate Cancer Diagnostics and Therapy Market Share by Application (2017-2028)
9.4 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Country
9.4.1 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Country (2017-2022)
9.4.2 Latin America Prostate Cancer Diagnostics and Therapy Market Size by Country (2023-2028)
9.4.3 Mexico
9.4.4 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size (2017-2028)
10.2 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method
10.2.1 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2017-2022)
10.2.2 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Treatment Method (2023-2028)
10.2.3 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Share by Treatment Method (2017-2028)
10.3 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Application
10.3.1 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Application (2017-2022)
10.3.2 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Application (2023-2028)
10.3.3 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Share by Application (2017-2028)
10.4 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Country
10.4.1 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Country (2017-2022)
10.4.2 Middle East & Africa Prostate Cancer Diagnostics and Therapy Market Size by Country (2023-2028)
10.4.3 Turkey
10.4.4 Saudi Arabia
10.4.5 UAE
11 Key Players Profiles
11.1 Ipsen SA
11.1.1 Ipsen SA Company Details
11.1.2 Ipsen SA Business Overview
11.1.3 Ipsen SA Prostate Cancer Diagnostics and Therapy Introduction
11.1.4 Ipsen SA Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.1.5 Ipsen SA Recent Developments
11.2 Pfizer Inc.
11.2.1 Pfizer Inc. Company Details
11.2.2 Pfizer Inc. Business Overview
11.2.3 Pfizer Inc. Prostate Cancer Diagnostics and Therapy Introduction
11.2.4 Pfizer Inc. Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.2.5 Pfizer Inc. Recent Developments
11.3 Johnson & Johnson Services Inc.
11.3.1 Johnson & Johnson Services Inc. Company Details
11.3.2 Johnson & Johnson Services Inc. Business Overview
11.3.3 Johnson & Johnson Services Inc. Prostate Cancer Diagnostics and Therapy Introduction
11.3.4 Johnson & Johnson Services Inc. Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.3.5 Johnson & Johnson Services Inc. Recent Developments
11.4 Bayer AG
11.4.1 Bayer AG Company Details
11.4.2 Bayer AG Business Overview
11.4.3 Bayer AG Prostate Cancer Diagnostics and Therapy Introduction
11.4.4 Bayer AG Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.4.5 Bayer AG Recent Developments
11.5 Abbvie Inc.
11.5.1 Abbvie Inc. Company Details
11.5.2 Abbvie Inc. Business Overview
11.5.3 Abbvie Inc. Prostate Cancer Diagnostics and Therapy Introduction
11.5.4 Abbvie Inc. Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.5.5 Abbvie Inc. Recent Developments
11.6 Merck & Co. Inc.
11.6.1 Merck & Co. Inc. Company Details
11.6.2 Merck & Co. Inc. Business Overview
11.6.3 Merck & Co. Inc. Prostate Cancer Diagnostics and Therapy Introduction
11.6.4 Merck & Co. Inc. Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.6.5 Merck & Co. Inc. Recent Developments
11.7 AstraZeneca PLC
11.7.1 AstraZeneca PLC Company Details
11.7.2 AstraZeneca PLC Business Overview
11.7.3 AstraZeneca PLC Prostate Cancer Diagnostics and Therapy Introduction
11.7.4 AstraZeneca PLC Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.7.5 AstraZeneca PLC Recent Developments
11.8 Thermo Fisher Scientific
11.8.1 Thermo Fisher Scientific Company Details
11.8.2 Thermo Fisher Scientific Business Overview
11.8.3 Thermo Fisher Scientific Prostate Cancer Diagnostics and Therapy Introduction
11.8.4 Thermo Fisher Scientific Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.8.5 Thermo Fisher Scientific Recent Developments
11.9 Dendreon Pharmaceuticals LLC
11.9.1 Dendreon Pharmaceuticals LLC Company Details
11.9.2 Dendreon Pharmaceuticals LLC Business Overview
11.9.3 Dendreon Pharmaceuticals LLC Prostate Cancer Diagnostics and Therapy Introduction
11.9.4 Dendreon Pharmaceuticals LLC Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.9.5 Dendreon Pharmaceuticals LLC Recent Developments
11.10 F. Hoffmann-La Roche Ltd
11.10.1 F. Hoffmann-La Roche Ltd Company Details
11.10.2 F. Hoffmann-La Roche Ltd Business Overview
11.10.3 F. Hoffmann-La Roche Ltd Prostate Cancer Diagnostics and Therapy Introduction
11.10.4 F. Hoffmann-La Roche Ltd Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.10.5 F. Hoffmann-La Roche Ltd Recent Developments
11.11 Hologic Inc.
11.11.1 Hologic Inc. Company Details
11.11.2 Hologic Inc. Business Overview
11.11.3 Hologic Inc. Prostate Cancer Diagnostics and Therapy Introduction
11.11.4 Hologic Inc. Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.11.5 Hologic Inc. Recent Developments
11.12 Astellas Pharma Inc.
11.12.1 Astellas Pharma Inc. Company Details
11.12.2 Astellas Pharma Inc. Business Overview
11.12.3 Astellas Pharma Inc. Prostate Cancer Diagnostics and Therapy Introduction
11.12.4 Astellas Pharma Inc. Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.12.5 Astellas Pharma Inc. Recent Developments
11.13 Koninklijke Philips NV
11.13.1 Koninklijke Philips NV Company Details
11.13.2 Koninklijke Philips NV Business Overview
11.13.3 Koninklijke Philips NV Prostate Cancer Diagnostics and Therapy Introduction
11.13.4 Koninklijke Philips NV Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.13.5 Koninklijke Philips NV Recent Developments
11.14 Sanofi-Aventis
11.14.1 Sanofi-Aventis Company Details
11.14.2 Sanofi-Aventis Business Overview
11.14.3 Sanofi-Aventis Prostate Cancer Diagnostics and Therapy Introduction
11.14.4 Sanofi-Aventis Revenue in Prostate Cancer Diagnostics and Therapy Business (2017-2022)
11.14.5 Sanofi-Aventis Recent Developments
12 Analyst’s Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Author Details
13.3 Disclaimer